Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy
Clinical trial NCT05152212 · COMPLETED
Trial details
- NCT number
- NCT05152212
- Sponsor
- Lyvgen Biopharma Holdings Limited
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-29
- Primary completion
- 2023-12-19
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.